stockmarketproxy
/
AXSMNasdaq SEC EDGAR

Axsome Therapeutics, Inc.

Pharmaceutical Preparations·NEW YORK, NY·FY end 12/31·CIK 1579428
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$638.5M$385.7M$270.6M$50.0M—
Gross Profit——————
Operating Income-$166.8M-$280.6M-$231.8M-$179.8M-$124.7M
Net Income-$183.2M-$287.2M-$239.2M-$187.1M-$130.4M
Operating CF-$93.4M-$128.4M-$145.1M-$116.5M-$108.2M
Capex$480.0K$270.0K$582.0K$702.1K$307.5K
Free Cash Flow-$93.9M-$128.7M-$145.7M-$117.2M-$108.5M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin-26.1%-72.7%-85.7%-359.3%—
Net Margin-28.7%-74.5%-88.4%-374.0%—
FCF Margin-14.7%-33.4%-53.8%-234.3%—
R&D / Revenue28.7%48.5%36.2%115.8%—
Effective Tax0.3%-0.0%-0.4%——
Debt / Equity1.333.170.930.863.14
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
AXSM
23:1
ROIV
518:1
COGT
95:1
PFE
277:1
ABT
166:1
PTCT
7:1
CEO total comp
AXSM
$34M
ROIV
$163M
COGT
$28M
PFE
$28M
ABT
$24M
PTCT
$23M
Net Margin
AXSM
-28.7%
ROIV
-592.0%
COGT
—
PFE
12.4%
ABT
14.7%
PTCT
39.4%